Quality of individual <font color="red">INR_1</font> control and the risk of <font color="red">stroke_1</font> <font color="red">and_1</font> <font color="red">bleeding_1</font> events in <font color="red">atrial_1</font> <font color="red">fibrillation_1</font> patients : a nested case control analysis of the ACTIVE W study . 
<br>
<br> INTRODUCTION <font color="red">Time_3</font> <font color="red">in_3</font> <font color="red">therapeutic_3</font> <font color="red">range_3</font> <font color="red">(_3</font> <font color="red">TTR_3</font> <font color="red">)_3</font> <font color="red">for_1</font> <font color="red">international_2</font> <font color="red">normalized_2</font> <font color="red">ratio_2</font> <font color="red">(_2</font> <font color="red">INR_2</font> <font color="red">)_2</font> is an accepted quality measure of <font color="red">anticoagulation_1</font> control in patient populations , but its usefulness for predicting <font color="red">stroke_1</font> <font color="red">and_1</font> <font color="red">bleeding_1</font> in individuals is not well understood . 
<br> MATERIALS AND METHODS In a nested case control analysis among ACTIVE W study patients , cases with <font color="red">stroke_1</font> and cases with bleeding were separately matched with controls . <font color="red">Several_1</font> <font color="red">anticoagulation_2</font> <font color="red">quality_1</font> <font color="red">measures_1</font> were compared , overall and in a time - dependent manner . 
<br> RESULTS 32 cases with <font color="red">ischemic_1</font> <font color="red">stroke_1</font> and 234 cases with <font color="red">bleeding_1</font> in the analysis were matched in a 4:1 ratio to 122 and 865 <font color="red">controls_1</font> <font color="red">,_1</font> respectively . Follow - up duration was 257±154days for the <font color="red">stroke_2</font> <font color="red">analysis_1</font> and 222±146days for the <font color="red">bleeding_2</font> <font color="red">analysis_1</font> <font color="red">._1</font> Compared with their respective <font color="red">controls_1</font> <font color="red">,_1</font> the study mean <font color="red">TTR_2</font> of both <font color="red">stroke_2</font> <font color="red">cases_1</font> <font color="red">(_1</font> <font color="red">53.9%±25.1_1</font> <font color="red">vs_1</font> <font color="red">63.4%±24.8_1</font> <font color="red">;_1</font> <font color="red">p=0.055_1</font> <font color="red">)_1</font> and <font color="red">bleeding_1</font> <font color="red">cases_1</font> <font color="red">(_1</font> <font color="red">56.2%±25.4_1</font> <font color="red">vs_1</font> <font color="red">63.4%±26.8_1</font> <font color="red">;_1</font> <font color="red">p<0.001_1</font> <font color="red">)_1</font> <font color="red">was_1</font> lower . Time below range for <font color="red">stroke_2</font> and time above range for <font color="red">bleeding_1</font> were only greater in the last month leading up to the event , not over the entire study period . Rather , over the entire study period <font color="red">bleeding_2</font> <font color="red">cases_1</font> spent more time below range than <font color="red">controls_1</font> <font color="red">(_1</font> <font color="red">26.8%±25.9_1</font> <font color="red">vs_1</font> <font color="red">20.8%±24.0_1</font> <font color="red">;_1</font> <font color="red">p=0.001_1</font> <font color="red">)_1</font> <font color="red">._1</font> 
<br> CONCLUSIONS <font color="red">TTR_2</font> was lower in individual AF patients with stroke or bleeding compared with matched controls in ACTIVE W. Maintaining a high <font color="red">TTR_2</font> <font color="red">,_2</font> with equal importance to avoid low and high <font color="red">INRs_1</font> <font color="red">,_1</font> is a relevant goal of individual patient treatment to prevent <font color="red">stroke_1</font> <font color="red">and_1</font> <font color="red">bleeding_1</font> <font color="red">._1</font>